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Anovel one-pot synthesis of tri-substituted purines and the discovery of purine analogues with trypanocidal
activity are reported. The reaction is initiated by a metal-free oxidative coupling of primary alkoxides and
diaminopyrimidines with Schiff base formation and subsequent annulation in the presence of large
N,N-dimethylamides (e.g. N,N-dimethylpropanamide or larger). This synthetic route is in competitionwith
a reaction previously-reported by our group1, allowing the generation of a combinatorial library of
tri-substituted purines by the simple modification of the amide and the alkoxide employed. Among the
variety of structures generated, two purine analogues displayed trypanocidal activity against the protozoan
parasite Trypanosoma brucei with IC50, 5 mM, being each of those compounds obtained through each of
the synthetic pathways.
P
urines are one of the most widely occurring heterocycles in nature2. This class of fused [655] nitrogen-
containing heterocycles are the core structure of nucleobases (e.g. adenine and guanine, essential building
blocks of biological structures), and of a wide range of natural compounds with pharmacological properties,
including alkaloids (e.g. caffeine and theobromine), cytokines, and natural antibiotics2, thus being considered
privileged scaffolds for drug development3,4. Due to their similarity with cell components, purine analogues may
act as substrates or inhibitors of enzymes of purine metabolism5 or as agonists/antagonists/inhibitors of aden-
osine receptors6 and protein kinases7. This is particularly relevant in the development of antiparasitic che-
motherapies, since most parasites rely heavily on purine salvage pathways as they cannot synthesize them de
novo8. Purine libraries decorated with different substituents might thus be expected to have a high probability of
yielding bioactive compounds and, consequently, purine-derived compounds have been subject to vast explora-
tion in both the heterocyclic and the medicinal chemistry fields9–12. As a result, a number of pharmacologically-
active purine analogues have been approved for their clinical application as chemotherapeutic agents (antiviral,
antiprotozoal, antifungal and anticancer agents13,14) and as pharmacodynamic drugs (coronary vasodilator)15.
Therefore, the development of diversity generating methods to synthesize novel poly-substituted purines poten-
tially represents a rapid source of drug candidates for several therapeutic applications16.
Due to their low cost, commercial availability and the range of well-established synthetic protocols existing in
the literature, the most common starting material used to generate purine analogues are pyrimidines17–20. Over a
decade ago1, we reported the one-pot synthesis of poly-substituted purines (5) from 4-alkylamino-5-amino-6-
chloropyrimidines (4), primary alkoxides (2) and eitherN,N-dimethylformamide orN,N-dimethylacetamide (1)
(Fig. 1). Alkoxide anions were formed in excess by reaction of sodium hydride and the corresponding primary
alcohols. It was proposed that reactive species (alkoxyiminium 3) was generated in situ by reaction between the
amide 1 and the alkoxides 2, leading to poly-substituted purine analogues with either H or methyl at C8
depending on the amide employed. This mechanism was supported by the formation of the expected purine
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analogues using dimethylformamide dimethylacetal (orthoamide).
SNAr of the chloro atom at C6 by various alkoxides and the R3 group
of the pyrimidine was used to implement structural diversity, thus
allowing the straightforward generation of a 12-member library of
purine analogues.
Results and Discussion
Motivated by the potential pharmacological properties of these pri-
vileged structures, we revisited this methodology to create a new
library of poly-substituted purines using a range of different pyrimi-
dines,N,N-dimethylamides and alcohols. Interestingly, following the
same procedure, purines 9 and 10were isolated after reaction ofN,N-
dimethylacetamide 6, benzyl alkoxide 7 (in situ generated by reaction
of sodium hydride and benzyl alcohol) and 5-amino-6-chloro-4-
isopropylaminopyrimidine 8 (Fig. 2). The unexpected formation of
purine analogue 10 suggested that the substituent at C8 originated
from the benzyl alkoxide 7 rather than from the amide 6. During the
investigation of the possible mechanism involved in the synthesis of
purine 10, the use of dialkylacetals (orthoamide) as alkoxyiminium
ion synthons to obtain quinazolines from anthranilamides was
reported21, which endorsed the mechanism proposed in Fig. 1 but
left the formation of purine 10 unexplained. Together with the fact
that alkoxyiminium ions are also considered a source of very reactive
species capable of doing electrophilic N-alkylation22, the intriguing
generation of purine 10 and the potential versatility of the process
prompted us to both investigate and exploit this synthetic method
further.
A set of reactions were planned to generate new purine analogues
and, in turn, finding out key aspects of themechanism throughwhich
purine 10 was formed. Reactions among 4-alkylamino-5-amino-6-
chloropyrimidines, N,N-dimethylamides and different alcohol
sources were carried out. Following purification and characteriza-
tion, products were classified into two categories: (i) type A purines,
containing a C8 substituent (R1) derived from the amide used, and
(ii) type B purines, with the C8 substituent (R2) revealing an alternate
mechanism where the cyclo-condensation agent appeared to origin-
ate from the alcohol/alkoxide species (see Fig. 3).
Figure 1 | Plausible mechanism of the one-pot synthesis of poly-substituted purines previously developed by our group1.
Figure 2 | Expected and unexpected products obtained by reaction of
N,N-dimethylacetamide, benzyl alkoxide (benzyl alcohol 1 sodium
hydride), and 5-amino-6-chloro-4-isopropylamino-pyrimidine.
www.nature.com/scientificreports
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Table 1 summarizes the reactions performed and themajor purine
analogue isolated (see Fig. 3 for chemical structures of both type of
compounds). It was clearly observed that steric features of the reac-
tants played a key role in determining towards which route the reac-
tion occurs. Large amides such as N,N-dimethylisopropionamide
and N,N-dimethylbenzamide (R15 iPr or Ph) gave rise to type B
purines with each of the alcohols used (entries B5–9). Similarly,
the use of N,N-dimethylpropionamide (R1 5 Et) with benzyl or p-
methoxybenzyl alcohols (bulky R2) led to type B analogues (entries
B1-4). Interestingly, type A purines were the major products when
N,N-dimethylpropionamide (R1 5 Et) was used together with a small
alcohol such as ethanol (entry A2 and 3), and when a smaller amide
such as N,N-dimethylacetamide were used (entry A1). Minor traces
of type B (,2.5%) analogues were also isolated from these reactions,
showing a competition between both routes. In accordance with
previous observation1, reactions developed with N,N-dimethylfor-
mamide exclusively produced type A purine analogues regardless
the alcohol employed (entries A4 and 5).
This synthetic study demonstrates competition between two dif-
ferent synthetic pathways, with the kinetics of intermediate forma-
tion for route A and B driving the final outcome. When the amide
employed is small (e.g. DMF), reaction between amides and alkox-
ides will form reactive alkoxyiminium (3) species that will lead to
type A analogues. On the contrary, route B governs the synthetic
process in the presence of larger N,N-dimethylamides, suggesting
that either the resulting alkoxyiminium (3) species is too stable/
sterically hindered to be attacked by the diaminopyrimidines or its
own formation is hindered by the size of the amide.
As mentioned before, examination of the type B purines synthe-
sized clearly indicated that their C8 substituents were originated
from the primary alcohols/alkoxides (R2). Since a carbon electrophi-
lic center directly derived from an alcohol could only mediate amine
alkylation, any synthetic pathway leading to route B would necessar-
ily involve an oxidation step (e.g. of the alcohol/alkoxide into the
corresponding aldehyde or the N-alkylated pyrimidine to the Schiff
base), which would in turn act as the cyclo-condensation agent. We
anticipated that introducing steric impediments in the startingmate-
rials could allow the trapping of the imine intermediate before the
cyclization is completed, thus proving the transitional formation of
Schiff base. To this end,N,N-dimethylbenzamide 11, benzyl alkoxide
7 and 5-amino-4-benzylamino-6-chloropyrimidine 12 were hand-
picked and subjected to the same reaction conditions. As a result
(Fig. 4), Schiff base intermediate 13 was isolated without detectable
formation of the purine analogue, corroborating the involvement
of an oxidative coupling of benzyl alcohol and 5-amino-4-
benzylamino-6-chloropyrimidine 12 as the essential initiating step
required to generate type B purine analogues.
Since reagents with higher oxidation states than aldehydes are
typically required to cyclo-condense and give rise to an aromatic
heterocycle23–26, a second oxidative step will need to occur for driving
the transformation of an unstable dihydropurine intermediate27
(resulting from the intramolecular attack of the alkylamino group
in C4 to the imine) into a purine system and thus complete synthetic
route B. Therefore, overall, synthesis of type B purine analogues
would require two oxidative steps for completion: first, oxidative
coupling of an alcohol and an exocyclic amine group to generate a
Schiff base (able to transitionally generate a dihydropurine deriv-
ative); and second, the oxidative generation of a purine system from
an unstable 7,8-dihydropurine intermediate28. Literature provide dif-
ferent examples of each of this oxidative steps independently but, to
Figure 3 | One-pot synthesis of poly-substituted purines using sodium
hydride and different N,N-dimethylamides, primary alcohols and 4-
alkylamino-5-amino-6-chloropyrimidines.
Table 1 | List of starting materials employed and the types of poly-substituted purines synthesized. Half-inhibitory concentrations (IC50)
against the protozoan parasite Trypanosoma brucei presented as mean 6 SEM. n 5 6
entry R1 R2 R3 ‘‘A’’% (R1, R2, R3) ‘‘B’’% (R2,R3) IC50 (mM)a T.brucei
A1 Me Ph iPr 16% traces 69.2 6 1.8
A2 Et Me iPr 29% traces 137.1 6 6.9
A31 Et Me Bu 31% traces 51.8 6 3.3
A4 H Me iPr 44% - 14.7 6 0.6
A5 H Ph iPr 38% - 1 6 0.1
B1 Et Ph iPr - 40% 52.1 6 1
B2 Et Ph tBu - 45% 18.3 6 0.5
B3 Et MeOPh iPr - 28% 42.7 6 1
B4 Et MeOPh tBu - 22% 80.5 6 3.5
B5 iPr H iPr - 10% 37.5 6 1.5
B6 iPr Me iPr - 10% 32 6 1.7
B7 Ph Me iPr - 20% 22.7 6 1.4
B8 Ph Et iPr - 27% 4.8 6 0.2
B9 Ph iPr iPr - 22% 12.6 6 0.6
aCell viability was assessed by resazurin dye. Half-inhibitory concentration (IC50) values were calculated using GraphPad Prism5 Software and defined as the concentration of purine required to diminish
fluorescence output by 50%. n 5 6.
www.nature.com/scientificreports
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our knowledge, this is the first time that both are reported concomi-
tantly to obtain substituted purines. For instance, a recent study has
reported the use of NaH/air as the oxidant source to obtain aldehyde
from alcohols without the need of using metals as catalyst29. Within
this line of research, three differentmanuscripts have reportedmetal-
free oxidative coupling of alcohols and amines, mediated by strong
basic conditions, to give rise to either imine or alkylated amines.30–32.
The synthesis of purine rings from diaminopyrimidines using both
aromatic and aliphatic aldehydes and an iron catalyst has also
been previously described33. Furthermore, evidences of metal-free
oxygen-promoted oxidation of electron-poor heterocycles in strong
basic conditions have been shown by us34 and others35. With these
precedents in mind, a set of reactions using reagents with large sub-
stituents (so that Route B pathway was to be favored) were designed
to shed some light on the oxidative aspects of route B mechanism.
Three reactions were performed in parallel withNaH and pyrimidine
8 as starting material and: (i) benzyl alcohol 7 and N,N-dimethyl-
propionamide 14 in argon atmosphere (oxygen-free environment),
(ii) amide-free reaction with benzyl alcohol 7 and (iii) amide-free
reaction with benzaldehyde 16 instead of benzyl alcohol (Fig. 5).
In the absence of oxygen, reaction (i) yielded a mixture of the
purine end-product 10 and Schiff base intermediate 15. This finding
was, in principle, contradictory to previous report asmetal-free oxid-
ative couplings are achieved under aerobic conditions. However, this
could be explained by presence of oxygen traces coming from the
cylinder, an observation also found by Adimurthy30 The presence of
Schiff base intermediate 15 shows the importance of oxygen as a
promoter of the second oxidation step.When the process was carried
out in the absence of the amide (panel (ii) of Fig. 5) and using dioxane
as solvent the reaction did not take place and the starting material 8
was recovered. To shed light into the role of the amide in the reaction,
the same reaction was repeated with toluene instead of dioxane as
Adimurthy30 observed that oxidative iminations are promoted in
toluene but not in dioxane. In agreement with Adimurthy’s observa-
tions, Schiff base intermediate 15 was obtained under these condi-
tions. Interestingly, purine 10 was not formed, highlighting the
assisting role of amides in the annulation step but not for the oxid-
ative imination.
Figure 4 | Synthesis of Schiff base 13 by sterically-hindered starting
materials.
Figure 5 | Study of the significance of different chemical reactants on the generation of type B analogues.
www.nature.com/scientificreports
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We then investigated if aldehyde intermediates, which would appear
to be the oxidative intermediate needed for Schiff base formation in the
first step, could be identified. Reaction of benzaldehyde 16, NaH and
pyrimidine 8 (condition (iii)) gave rise to purine 10 and Schiff base 15,
demonstrating that the direct use of the aldehyde36 can lead to the end-
products without the need of the amide, meaning that at this point the
aldehyde intermediate hypothesis was still credible. In this case and
remarkably, while benzyl alcohol 7 was not present in the reaction
mixture, C6-benzoxy products were obtained, suggesting a partial re-
duction of benzaldehyde into benzyl alkoxide probably mediated by
NaH37. We then carried out a set of reactions to try to capture the
aldehyde intermediate, which might be transitionally created in-situ.
2,4-dinitrophenylhydrazine was chosen as indicator in substitution of
the pyrimidine, aiming that upon reaction with the expected aldehyde
intermediate would create a hydrazone with a colour change. Benzyl
alcohol 7, N,N-dimethylpropanamide 14 and NaH were used as the
other reagents under the same conditions mentioned above. However,
only 2,4-dinitrophenylhydrazine decomposition was observed, likely due
to the strong basic conditions of the reaction. Reactions using just benzyl
alcohol 7,N,N-dimethylpropanamide 14 andNaH, in the absence of any
amino-containing starting material, were then carried to try to identify
benzaldehyde by TLC. However, no traces of benzaldehyde 16 were
detected. Hence, we could not identify aldehyde species under any of
these conditions and, even though Adimurthy reported the presence of
1%-2% of in situ generated catalytic aldehyde as the responsible species
to trigger these reactions, we cannot confirm that, in our case, the
oxidative imination takes place through aldehyde intermediates.
To summarize, the following features of the process have been
gathered from these studies are:
. There is competition between alkoxyiminium ion formation (cre-
ated by reacting N,N-dimethylamides and alkoxide) and metal-
free oxidative imination (reaction between amine and alcohols
assisted by strong basic conditions in open systems). When large
N,N-dimethylamides (R1 5 Et, iPr, Ph) are used, the formation of
alkoxyiminium ions is disfavoured and therefore purine forma-
tion via oxidative imination governs. In case of using smallerN,N-
dimethylamides (R1 5 H, Me), alkoxyiminium ion formation is
formed faster and purines type A are obtained (Fig. 6).
. There is no evidence of neither NaH to be directly involved in the
oxidation steps nor aldehyde to be the intermediate required to
obtain the Schiff base.
. Final products from reactions (i) and (iii) and the starting mater-
ial recovered from reaction (ii) demonstrate that SNAr of the
chloro atom at C6 by the alkoxide takes place upon formation
of the Schiff base in a rapid manner.
. While the second oxidation step (purine formation) does not
require the presence of the amide, the type of solvent influences
whether the annulation step does or does not take place.
Incomplete reactions (i) and (iii) indicate that oxygen and strong
basic conditions are promoters of the purine ring formation.
The second part of the work was to investigate whether the
chemical diversity produced through the described synthetic
methodology had resulted in the generation of biologically active
purines. Bearing in mind that purine salvage pathways have been
proposed as an interesting therapeutic target for pathogenic pro-
tozoa8,38 we decided to screen the antiparasitic properties of these
novel compounds against Trypanosoma brucei, the causative agent
of African trypanosomiasis, also known as sleeping sickness39.
Therefore, a trypanotoxicity assay using 11 different concentra-
tions of each of the library members was performed against blood-
stream forms of T. brucei. Half-inhibitory concentrations (IC50)
were determined for each of the compounds (Table 1). The
screening highlighted the trypanocidal properties of two deriva-
tives: compound B8 (ASIMJ-25), with an IC50 of 4.8 6 0.2 mM
mean 6 SEM), and the purine analogue A5 (ASIMJ-4) (Fig. 7),
which was the most active antiparasite compound of the series
with an IC50 of 1 6 0.1 mM (mean 6 SEM). Interestingly, these
active purines were generated through each of the synthetic
routes, and the only common feature was the isopropyl group at
the position 9 of the purine.
This inhibitory effect on trypanosomes growth was further
analyzed in compounds with the different IC50 values, including
the two most active compounds of the library, by optical and
fluorescence microscopy after DAPI staining. As expected, the
numbers of parasites on wells incubated with the selected inhi-
bitors A1 (ASIMJ-5), A5 (ASIMJ-4), B1 (ASIMJ-6), B2 (ASIMJ-
27) and B8 (ASIMJ-25), using their IC50 concentration values,
were much lower than on control wells. Moreover, all of these
compounds induced profound morphological changes in the
appearance of cells, with enlargement of the flagellar pocket
and multiple nuclei, which is a typical phenotype of dying trypa-
nosomes (Fig. 8)40,41.
Figure 6 | Proposed mechanisms of action for routes A and B. In accordance to the literature31, the imine intermediate can give rise, in a reversible
manner, to dihydropurines. The tandem synthetic process would end upon irreversible oxidation into purines.
www.nature.com/scientificreports
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Conclusions
In conclusion, a 14-member library of poly-substituted purines were
synthesized from 4-alkylamino-5-amino-6-chloropyrimidines using
primary alcohols, sodium hydride and N,N-dimethylalkyl/aryla-
mides. Competition between the formation of reactive alkoxyimi-
nium ions and the oxidation of alcohols defined which products
were obtained. In the absence of steric impediments, purine ana-
logues were synthesized via reaction of alkoxyiminium ions and
diaminopyrimidines. On the contrary, in the presence of larger
N,N-dimethylamides, a more complex synthetic route dominated,
giving rise to an unexpected set of purine analogues. The tandem
reaction sequence was initiated by a metal-free oxidative coupling of
primary alkoxide and exocyclic amino group at C4 of the pyrimidine
ring, obtaining a Schiff base intermediate. This intermediate under-
went an intramolecular cyclocondensation with the amino group at
C5 driven by an oxygen-promoted alkaline oxidation. Two Schiff
base intermediates were isolated and could be obtained in higher
yields by increasing the size of the substituents of the amides and
of the amino group found at C5 of the pyrimidine. The role of large
N,N-dimethylamides for the formation of Schiff base under these
conditions seems to be not crucial as toluene (but not dioxane) also
enabled the oxidative imination. However, N,N-dimethylamides
promoted the second oxidation step to obtain purine rings whereas
toluene did not, demonstrating the relevant role of the solvent in
the reaction cascade. One aspect that is still inconclusive is which
Figure 7 | Chemical structures of compounds A5 (ASIMJ-4) and B8
(ASIMJ-25), the most active of the library against the protozoan parasite
Trypanosoma brucei.
Figure 8 | Confocal fluorescence and optical microscopy DIC of bloodstream trypanosomes incubated for 24 h with IC50 concentrations of A1 (AIMJ-
5), A5 (ASIMJ-4), B1 (ASIMJ-6), B2 (ASIMJ-27), B8 (ASIMJ-25) and controls. DAPI channel stain nucleus (N) and kinetoplast (K).
www.nature.com/scientificreports
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alcohol-derived species carry out the oxidative couplings with amino
groups. In this study we could not confirm that the oxidative imina-
tion happened via an aldehyde intermediate.
To the best of our knowledge, this tandem synthetic process has
been described herein for the first time. From a synthetic/medicinal
point of view, and even if the reaction yields are low to moderate, the
interest of the present methodology relies on its versatility, since it
allows to generate a range of different tri-substituted purine analo-
gues by the simple selection of readily available starting materials.
Finally, we have shown the capacity of some of these novel purine
derivatives to reduce trypanosome viability by inducing an enlarged
flagellar pocket phenotype with one compound, A5 (ASIMJ-4), pre-
senting an IC50 value of 1 mM. Given the relatively small molecular
weight of this compound (MW5 263 Da), compoundA5(ASIMJ-4)
could be considered a fragment with unusually high phenotypic
activity. These interesting results underscore the importance of
developing short and versatile synthetic pathways capable of gen-
erating structural diversity in order to produce novel purine libraries,
in rapid parallel fashions, with pharmacological/therapeutic interest.
Experimental Section
General Experimental. Reaction courses and products mixtures where routinely
monitored by TLC on silica gel Merck 60–200 mesh silica gel. Melting points were
determined on a Stuart Scientific SMP3 apparatus and are uncorrected. 1H-NMR
spectra were obtained in CDCl3, CD3OD solutions on a Varian Inova Unity
(300 MHz) and Varian Direct Drive (400 MHz and 500 MHz). Chemical shifts (d)
are given in ppm upfield from tetramethylsilane. 13C-NMR spectra were obtained in
CDCl3, CD3OD solutions on aVarianDirect Drive (125 MHz). All products reported
showed 1H-NMR and 13C-NMR spectra in agreement with the assigned structures.
Mass spectra were obtained by electrospray (ESY) with a LCT Premier XEMicromass
Instrument (High resolution mass spectrometry).
General procedure for the preparation of compounds B1-9 (Route B). NaH (50%) in
mineral oil (3.7 mmol, 10 equiv.) was added to amixture cooled at 0uC constituted of
the corresponding alcohol (3.7 mmol, 10 equiv.) and N,N-dimethylamide
(18.5 mmol, 50 equiv.). In case of using N,N-dimethylbenzamide, 1,4-dioxane
(2 mL) was used as solvent. The solution was stirred at room temperature for 30 min
and then at 90uC for another 30 min. After this time, substituted pyrimidines
(0.37 mmol, 1 equiv., 5-amino-6-chloro-4-isopropylaminopyrimidine 8 or 5-amino-
4-tert-butylamino-6-chloropyrimidine, which prepared as described elsewhere1)
were dissolved either in the same amide (18.5 mmol, 50 equiv.) or in 1,4-dioxane
(2 mL, in the case of N,N-dimethylbenzamide) and added dropwise to the mixture,
which was then heated for 24 h at 90uC. The reaction mixture was brought to pH 7
with an aq. saturated NH4Cl solution, and then extracted with CH2Cl2 (3 3 15 mL).
The combined organic extracts were dried over Na2SO4, filtered and the organic
solvent evaporated. Crudes were purified by flash chromatography on silica gel using
ethyl acetate/petroleum ether as mobile phases.
6-Benzyloxy-9-isopropyl-8-phenyl-9H-purine (B1)ASIMJ-6. White solid, mp 111–
112uC; yield 40%. dH (300.20 MHz, CDCl3): 8.57 (1H, s, NCHN), 7.70–7.38 (10H, m,
Ph, CH2Ph), 5.72 (2H, s, OCH2Ph), 4.80 (1H, m, CH(CH3)2), 1.76 (6H, d, J 5 6 Hz,
NCH(CH3)2). dC (125.68 MHz, CDCl3): 160.54, 153.14, 151.01, 136.66, 130.40,
129.80, 128.95, 128.76, 128.61, 128.27, 128.05, 122.14, 68.42, 50.04, 21.51. ES 1
HRMS: Calculated M 1 H5 345.1715. C21H21N4O. Obtained: 345.1716.
9-tert-butyl-6-(benzyloxy)-8-phenyl-9H-purine (B2) ASIMJ-27. White solid, mp:
113–114uC; yield 45%. dH (300.20 MHz, CDCl3): 8.59 (1H, s, NCHN), 7.58–7.34
(10H, m, Ph, CH2Ph), 5.69 (2H, s, OCH2Ph), 1.70 (9H, s, NC(CH3)3). dC
(125.68 MHz, CDCl3): 160.62, 154.52, 153.37, 150.46, 136.58, 134.97, 130.11, 129.72,
128.85, 128.59, 128.27, 128.09, 121.76, 68.43, 61.06, 31.15. ES1HRMS: CalculatedM
1 H 5 359.1872. C22H23N4O. Obtained: 359.1880.
6-(3-methoxybenzyloxy)-9-isopropyl-8-(3-methoxyphenyl)-9H-purine (B3). White
viscous oil; yield 28%. dH (499.79 MHz, CDCl3): 8.53 (1H, s, NCHN), 7.44–6.85 (8H,
m, Ph, CH2Ph), 5.66 (2H, s, OCH2Ph), 4.79 (1H, m, CH(CH3)2), 3.87 (3H, s,
OCH2PhOCH3), 3.80 (3H, s, PhOCH3), 1.72 (6H, d, NCH(CH3)2). dC (125.68 MHz,
CDCl3): 160.27, 159.64, 153.59, 152.75, 150.76, 137.94, 131.25, 129.41, 121.63, 120.78,
116.25, 114.92, 113.88, 113.70, 68.03, 55.45, 55.26, 49.81, 21.26. ES 1 HRMS:
Calculated M 1 H5 405.1927. C23H25N4O3. Obtained: 405.1930.
6-(3-methoxybenzyloxy)-9-tert-butyl-8-(3-methoxyphenyl)-9H-purine (B4). Yellow
viscous oil; yield 22%. dH (400.57 MHz, CDCl3): 8.55 (1H, s, NCHN), 7.48–6.83 (8H,
m, Ph, CH2Ph), 5.63 (2H, s, OCH2Ph), 3.83 (3H, s, OCH2PhOCH3), 3.79 (3H, s,
PhOCH3), 1.68 (9H, s, NC(CH3)3). dC (125.68 MHz, CDCl3): 160.29, 159.61, 159.02,
154.21, 152.87, 150.23, 137.83, 129.38, 128.92, 122.49, 120.86, 119.08, 115.41, 113.91,
113.29, 112.24, 68.06, 55.40, 55.27, 30.76. ES 1 HRMS: Calculated M 1 H 5
419.2083. C24H27N4O3. Obtained: 419.2086.
9-Isopropyl-6-methoxy-9H-purine (B5). White viscous oil; yield 10%. dH
(400.57 MHz, CDCl3): 8.53 (1H, s, NCHN), 7.98 (1H, s, NHCHNiPr), 4.89 (1H, m,
CH(CH3)2), 4.18 (3H, s, OCH3), 1.63 (6H, d, J 5 8 Hz, NCH(CH3)2).
dC(125.68 MHz, CDCl3): 161.19, 152.25, 151.86, 139.89, 122.07, 54.26, 47.63, 22.78.
ES 1 HRMS: Calculated M 1 H: 193.1089. C9H13N4O. Obtained: 193.1087.
6-Ethoxy-9-isopropyl-8-methyl-9H-purine (with N,N-dimethylisopropionamide)
(B6). Yellow viscous oil; yield 10%. dH(499.79 MHz, CDCl3): 8.44 (1H, s, NCHN),
4.73 (1H, m, CH(CH3)2), 4.62 (2H, q, J 5 10 Hz, OCH2CH3), 2.64 (3H, s, CH3), 1.68
(6H, d, J 5 5 Hz, NCH(CH3)2), 1.50 (3H, t, J 5 10 Hz, OCH2CH3). dC(125.68 MHz,
CDCl3): 159.74, 152.88, 151.75, 150.53, 120.71, 62.67, 48.31, 21.24, 15.22, 14.58. ES 1
HRMS: Calculated M 1 H 5 221.1402. C11H17N4O. Obtained: 221.1401.
6-Ethoxy-9-isopropyl-8-methyl-9H-purine (with N,N-dimethylbenzamide) (B7).
Yellow viscous oil; yield 20%. dH(499.79 MHz, CDCl3): 8.44 (1H, s, NCHN), 4.73
(1H, m, CH(CH3)2), 4.62 (2H, q, J 5 10 Hz, OCH2CH3), 2.64 (3H, s, CH3), 1.68 (6H,
d, J 5 5 Hz, NCH(CH3)2), 1.51 (3H, t, J 5 10 Hz, OCH2CH3). dC(125.68 MHz,
CDCl3): 159.74, 152.88, 151.75, 150.53, 120.71, 62.67, 48.31, 21.24, 15.22, 14.58. ES 1
HRMS: Calculated M 1 H 5 221.1402. C11H17N4O. Obtained: 221.1396.
8-Ethyl-9-isopropyl-6-propoxy-9H-purine (B8)ASIMJ-25. Yellow viscous oil; yield
27% dH (300.20 MHz, CDCl3): 8.43 (1H, s, NCHN), 4.69 (1H, m, CH(CH3)2), 4.52
(2H, t, J 5 9 Hz, OCH2CH2CH3), 2.94 (2H, q, J 5 6 CH2CH3), 1.92 (2H, m,
OCH2CH2CH3), 1.70 (6H, d, J 5 10 Hz, NCH(CH3)2), 1.43 (3H, t, J 5 6 Hz,
CH2CH3), 1.05 (3H, t, J 5 9, OCH2CH2CH3). dC(125.68 MHz, CDCl3): 160.28,
155.28, 150.65, 150.31, 124.41, 68.65, 48.57, 21.24, 23.13, 22.49, 21.51, 12.49, 10.66. ES
1 HRMS: Calculated M 1 H 5 249.1715. C13H21N4O. Obtained: 249.1721.
6-Isobutoxy-8,9-diisopropyl-9H-purine (B9). White viscous oil; yield 22%. dH
(300.20 MHz, CDCl3): 8.44 (1H, s, NCHN), 4.74 (1H, m, NCH(CH3)2), 4.36 (2H, d,
OCH2Pri, J 5 9 Hz), 3.28 (1H, m, CCH(CH3)2), 2.29 (1H, m, CH2CH(CH3)2), 1.72
(6H, d, J 5 9 Hz, NCH(CH3)2), 1.47 (6H, d, J 5 9 Hz, CCH(CH3)2), 1.06 (6H, d, J 5
9 Hz, CH2CH(CH3)2). ES 1 HRMS: Calculated M 1 H 5 277.2028. C15H25N4O.
Obtained: 277.2036.
General procedure for the preparation of compounds A1-5 (Route A). NaH (50%) in
mineral oil (3.7 mmol, 10 equiv.) was added to amixture cooled at 0uC constituted of
the corresponding alcohol (3.7 mmol, 10 equiv.) and N,N-dimethylamide
(18.5 mmol, 50 equiv.). The solution was stirred at room temperature for 30 min and
then at 90uC for another 30 min. After this time, substituted pyrimidines (0.37 mmol,
1 equiv.) were dissolved in the amide (18.5 mmol, 50 equiv.) and added dropwise to
the mixture which was then heated for 24 h at 90uC. The reaction mixture was
brought to pH 7 with an aq. saturated NH4Cl solution, and then extracted with
CH2Cl2 (33 15 mL). The combined organic extracts were dried over Na2SO4, filtered
and the organic solvent evaporated. Crudes were purified by flash chromatography
on silica gel using ethyl acetate/petroleum ether as mobile phases.
6-(Benzyloxy)-9-isopropyl-8-methyl-9H-purine (A1)ASIMJ-5. White solid, mp: 84-
86uC; yield 16%. dH (499.79 MHz, CDCl3): 8.47 (1H, s, NCHN), 7.54–7.30 (5H, m,
Ph), 5.65 (2H, s, OCH2Ph), 4.75 (1H, m, CH(CH3)2), 2.65 (3H, s, CH3), 1.69 (6H, d, J
5 10 Hz, NCH(CH3)2). dC (125.68 MHz, CDCl3): 159.41, 153.57, 150.69, 150.41,
136.42, 128.43 128.35, 127.98, 120.73, 68.06, 48.35, 21.23, 15.22. ES 1 HRMS:
Calculated M 1 H 5 283.1559. C16H19N4O. Obtained: 283.1558.
6-Ethoxy-8-ethyl-9-isopropyl-9H-purine (A2). Yellow viscous oil; yield 29%.
dH(300.20 MHz, CDCl3): 8.47 (1H, s, NCHN), 4.72 (1H,m,CH(CH3)2), 4.67 (2H, q, J
5 6 Hz, OCH2CH3), 2.96 (2H, q, J 5 6, CH2CH3), 1.74 (6H, d, J 5 6 Hz,
NCH(CH3)2), 1.53 (3H, t, J 5 6 Hz, OCH2CH3), 1.47 (3H, t, J5 6 Hz, -CH2CH3). ES
1 HRMS: Calculated M 1 H 5 235.1559. C12H19N4O. Obtained: 235.1557.
6-Ethoxy-8-ethyl-9-(n-butyl)-9H-purine (A3). (This compound has already been
prepared by us and is described elsewhere1). Yellow viscous oil; yield 31%. dH
(200 MHz, CD3OD): 8.42 (1H, s, NCHN), 4.59 (2H, q, J 5 7.1 Hz, OCH2CH3), 4.23
(t, J 5 7.4 Hz, 2H), 2.93 (2H, q, J 5 7.5 Hz, CH2CH3), 1.79 (2H, m, NCH2CH2), 1.43
(3H, t, J 5 7.1 Hz, OCH2CH3), 1.39 (3H, t, J 5 7.5 Hz, -CCH2CH3), 1.38 (2H, m,
NCH2CH2CH2), 0.93 (3H, t, J 5 7.4 Hz, NCH2CH2CH2CH3). dC (75 MHz, CD3OD:
160.3, 156.3, 154.7, 151.4, 121.1, 62.9, 42.9, 32.5, 21.3, 20.5, 14.8, 13.9, 11.4. MS
(70 eV) m/z (%): 249.2 (M11); 271.1; 221.1.
6-Ethoxy-9-isopropyl-9H-purine (A4). Light yellow solid; yield 44%. dH (499.79 MHz,
CDCl3): 8.49 (1H, s, NCHN), 7.96 (1H, s, NHCHN), 4.88 (1H, m, CH(CH3)2), 4.64
(2H, q, J 5 5 Hz, OCH2CH3), 1.60 (6H, d, J 5 5 Hz, NCH(CH3)2), 1.49 (3H, t, J 5
5 Hz, OCH2CH3). dC (125.68 MHz, CDCl3): 160.81, 151.70, 139.53, 121.83, 62.98,
47.33, 22.60, 14.51. ES 1 HRMS: Calculated M 1 H 5 207.1246. C10H15N4O.
Obtained: 207.1245.
6-(Benzyloxy)-9-isopropyl-9H-purine (A5)ASIMJ-4.White solid; yield 38%; mp 167–
169uC. dH (499.79 MHz, CDCl3): 8.56 (1H, s, NCHN), 8.00 (1H, s, NHCHN), 7.56-
7.30 (5H, m, Ph), 5.69 (2H, s, OCH2Ph), 4.91 (1H, m, CH(CH3)2), 1.64 (6H, d, J 5
10 Hz, NCH(CH3)2). dC (125.68 MHz, CDCl3): 160.53, 151.63, 139.77, 136.27,
130.03, 128.41, 128.29, 128.05, 68.29, 47.43, 22.63. ES 1HRMS: CalculatedM1 H5
269.1402. C15H17N4O. Obtained: 269.1402.
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Concomitantly preparation of 6-benzyloxy-9-isopropyl-8-phenyl-9H-purine (10) and
6-benzyloxy-9-isopropyl-8-methyl-9H-purine (9) (Fig. 2). NaH (50%) in mineral oil
(3.7 mmol, 10 equiv.) was added to a mixture cooled at 0uC constituted of benzyl
alcohol (7.4 mmol, 20 equiv.) and N,N-dimethylacetamide (1.8 mL, 18.5 mmol,
50 equiv.). The solution was stirred at room temperature for 30 min and then at 90uC
for the same time. 5-amino-6-chloro-4-isopropylaminopyrimidine 8 (0.37 mmol,
1 equiv.) dissolved in N,N-dimethylacetamide (1.8 mL, 18.5 mmol, 50 equiv.) was
added dropwise to the mixture which was then heated for 24 h at 90uC. The reaction
mixture was brought to pH 7 with an aq. saturated NH4Cl solution, and then
extracted with CH2Cl2 (3 3 15 mL). The combined organic extracts were dried over
Na2SO4, filtered and the organic solvent evaporated. Crudes were purified by flash
chromatography on silica gel using ethyl acetate/petroleum ether as mobile phases.
Compounds 9 and 10 were isolated with 20% yield each.
6-Benzyloxy-9-isopropyl-8-methyl-9H-purine (9; Fig. 2). White solid; yield 20%. dH
(499.79 MHz, CDCl3): 8.47 (1H, s, NCHN), 7.54–7.30 (5H, m, Ph), 5.65 (2H, s,
OCH2Ph), 4.75 (1H, m, CH(CH3)2), 2.65 (3H, s, CH3), 1.69 (6H, d, J 5 10 Hz,
NCH(CH3)2). dC (125.68 MHz, CDCl3): 159.41, 153.57, 150.69, 150.41, 136.42,
128.43 128.35, 127.98, 120.73, 68.06, 48.35, 21.23, 15.22. ES 1 HRMS: Calculated M
1 H 5 283.1559. C16H19N4O. Obtained: 283.1555.
6-Benzyloxy-9-isopropyl-8-phenyl-9H-purine (10; Fig. 2). White solid, mp: 111–
112uC; yield 20%. dH (300.20 MHz, CDCl3): 8.57 (1H, s, NCHN), 7.70–7.38 (10H, m,
Ph, CH2Ph), 5.72 (2H, s, OCH2Ph), 4.80 (1H, m, CH(CH3)2), 1.76 (6H, d, J 5 6 Hz,
NCH(CH3)2). dC (125.68 MHz, CDCl3): 160.54, 153.14, 151.01, 136.66, 130.40,
129.80, 128.95, 128.76, 128.61, 128.27, 128.05, 122.14, 68.42, 50.04, 21.51. ES 1
HRMS: Calculated M 1 H 5 345.1715. C21H21N4O. Obtained: 345.1716.
Preparation of N4-benzyl-N5-benzylidene-6-(benzyloxy)pyrimidine-4,5-diamine (13)
(Fig. 4). NaH (50%) in mineral oil (3.7 mmol, 10 equiv.) was added to a mixture
cooled at 0uC constituted of benzyl alcohol (3.7 mmol, 10 equiv.) and N,N-
dimethylbenzamide (18.5 mmol, 50 equiv.) in 1,4-dioxane (2 mL). The solution was
stirred at room temperature for 30 min and then at 90uC for the same time. 5-amino-
4-benzylamino-6-chloropyrimidine 12 dissolved in 1,4-dioxane (2 mL) was added
dropwise to themixture whichwas then heated for 24 h at 90uC. The reactionmixture
was brought to pH 7 with an aq. saturated NH4Cl solution, and then extracted with
CH2Cl2 (33 15 mL). The combined organic extracts were dried over Na2SO4, filtered
and the organic solvent evaporated. Crudes were purified by flash chromatography
on silica gel using ethyl acetate/petroleum ether as mobile phases. Yellow oil; yield
10%. dH (499.79 MHz, CDCl3): 9.23 (1H, s, NCHPh), 8.21 (1H, s, NCHN), 8.01–7.35
(15H, m,NCHPh, NHCH2Ph, OCH2Ph), 5.53 (2H, s, OCH2Ph), 5.46 (2H, s,
NHCH2Ph), 4.82 (1H, d, J 5 5, Hz, NH). dC (125.68 MHz, CDCl3): 161.73, 158.71,
156.73, 144.68, 136.75, 134, 131.15, 128.71, 128.52, 128.10, 127.71, 127.34, 127.24,
114.20, 68.30, 44.98. ES 1 HRMS: Calculated M 1 H 5 395.1872. C25H23N4O.
Obtained: 395.1873.
Concomitantly preparation of 6-benzyloxy-9-isopropyl-8-phenyl-9H-purine (10) and
N5-benzylidene-6-(benzyloxy)-N4-isopropylpyrimidine-4,5-diamine (15) (Fig. 5 (i)).
In this case, in order to eliminate oxygen from the reaction, this was performed under
argon atmosphere. Furthermore, N,N-dimethylpropionamide was degassed by bub-
bling an argon stream assisted by an ultrasound device. NaH (50%) in mineral oil
(3.7 mmol, 10 equiv.) was added to a mixture cooled at 0uC constituted of benzyl
alcohol (3.7 mmol, 10 equiv.) and N,N-dimethylpropionamide (2.3 mL, 18.5 mmol,
50 equiv.). The solution was stirred at room temperature for 30 min and then at 90uC
for the same time. 5-amino-6-chloro-4-isopropylaminopyrimidine 8 (0.37 mmol,
1 equiv.) dissolved in N,N-dimethylpropionamide (2.3 mL, 18.5 mmol, 50 equiv.)
was added dropwise to the mixture which was then heated for 24 h at 90uC. The
reaction mixture was brought to pH 7 with an aq. saturated NH4Cl solution, and then
extracted with CH2Cl2 (3 3 15 mL). The combined organic extracts were dried over
Na2SO4, filtered and the organic solvent evaporated. Crudes were purified by flash
chromatography on silica gel using ethyl acetate/petroleum ether as mobile phases.
Compounds 10 and 15 were isolated with 20% yield each.
6-Benzyloxy-9-isopropyl-8-phenyl-9H-purine (10; Fig. 5 (i)). White solid, mp:111–
112uC; yield 23%. dH (300.20 MHz, CDCl3): 8.57 (1H, s, NCHN), 7.70–7.38 (10H, m,
Ph, CH2Ph), 5.72 (2H, s, OCH2Ph), 4.80 (1H, m, CH(CH3)2), 1.76 (6H, d, J 5 6 Hz,
NCH(CH3)2). dC (125.68 MHz, CDCl3): 160.54, 153.14, 151.01, 136.66, 130.40,
129.80, 128.95, 128.76, 128.61, 128.27, 128.05, 122.14, 68.42, 50.04, 21.51. ES 1
HRMS: Calculated M 1 H 5 345.1715. C21H21N4O. Obtained: 345.1718.
N5-Benzylidene-6-(benzyloxy)-N4-isopropylpyrimidine-4,5-diamine (15; Fig. 5 (i)).
Yellow oil; yield 10%. dH(499.79 MHz, CDCl3): 9.19 (1H, s, NCHPh), 8.18 (1H, s,
NCHN), 7.79 (2H, s, H-29NCHPh), 7.47–7.30 (8H, m, Ph, CHPh), 6.02 (1H, d, J 5
10 Hz, NH), 5.51 (2H, s, OCH2Ph), 4.35 (1H, m, CH(CH3)2), 1.32 (6H, d, J 5 5 Hz,
NCH(CH3)2). dC(125.68 MHz, CDCl3): 161.40, 158.53, 154.40, 137.34, 136.95,
134.49, 131.08, 128.75, 128.21, 127.68, 110.91, 68.02, 42.73, 23.23. ES 1 HRMS:
Calculated M 1 H 5 347.1872. C21H23N4O. Obtained: 347.1873.
Reaction of 5-amino-6-chloro-4-isopropylaminopyrimidine (8) with benzyl alcohol and
without amide (Fig. 5 (ii)).NaH (50%) inmineral oil (3.7 mmol, 10 equiv.) was added
to a mixture cooled at 0uC constituted of benzyl alcohol (3.7 mmol, 10 equiv.) and
1,4-dioxane (2 mL). The solution was stirred at room temperature for 30 min and
then at 90uC for the same time. 5-amino-6-chloro-4-isopropylaminopyrimidine 8
(0.37 mmol, 1 equiv.) dissolved in 1,4-dioxane (2 mL) was added dropwise to the
mixture which was then heated for 24 h at 90uC. The reactionmixture was brought to
pH 7 with an aq. saturated NH4Cl solution, and then extracted with CH2Cl2 (3 3
15 mL). The combined organic extracts were dried over Na2SO4, filtered and the
organic solvent evaporated. Crudes were purified by flash chromatography on silica
gel using ethyl acetate/petroleum ether. In this case, the starting materials were
recovered.
Preparation of 6-benzyloxy-9-isopropyl-8-phenyl-9H-purine (10) and N5-benzylidene-
6-(benzyloxy)-N4-isopropylpyrimidine-4,5-diamine (15) (Fig. 5 (iii). NaH (50%) in
mineral oil (3.7 mmol, 10 equiv.) was added to amixture cooled at 0uC constituted of
benzaldehyde (3.7 mmol, 10 equiv.) and 1,4-dioxane (2 mL). The solution was
stirred at room temperature for 30 min and then at 90uC for the same time. 5-amino-
6-chloro-4-isopropylaminopyrimidine 8 (0.37 mmol, 1 equiv.) dissolved in 1,4-
dioxane (2 mL) was added dropwise to themixture which was then heated for 24 h at
90uC. The reaction mixture was brought to pH 7 with an aq. saturated NH4Cl
solution, and then extracted with CH2Cl2 (3 3 15 mL). The combined organic
extracts were dried over Na2SO4, filtered and the organic solvent evaporated. Crudes
were purified by flash chromatography on silica gel using ethyl acetate/petroleum
ether asmobile phases. Compounds 10 and 15were isolated with a 23% yield and 10%
yield respectively.
6-Benzyloxy-9-isopropyl-8-phenyl-9H-purine (10; Fig. 5 (iii)).White solid; yield 23%.
dH (300 MHz, CDCl3): 8.57 (1H, s, NCHN), 7.70–7.38 (10H, m, Ph, CH2Ph), 5.72
(2H, s, OCH2Ph), 4.80 (1H, m, CH(CH3)2), 1.76 (6H, d, J 5 6 Hz, NCH(CH3)2). dC
(125.68 MHz, CDCl3): 160.54, 153.14, 151.01, 136.66, 130.40, 129.80, 128.95, 128.76,
128.61, 128.27, 128.05, 122.14, 68.42, 50.04, 21.51. ES 1HRMS: CalculatedM1 H5
345.1715. C21H21N4O. Obtained: 345.1718.
N5-Benzylidene-6-(benzyloxy)-N4-isopropylpyrimidine-4,5-diamine (15; Fig. 5 (iii)).
Yellow oil; yield 10%. dH (499.79 MHz, CDCl3): 9.19 (1H, s, NCHPh), 8.18 (1H, s,
NCHN), 7.79 (2H, s, H-29NCHPh), 7.47–7.30 (8H, m,Ph, CHPh), 6.02 (1H, d, J 5
10 Hz, NH), 5.51 (2H, s, OCH2Ph), 4.35 (1H, m, CH(CH3)2), 1.32 (6H, d, J 5 5 Hz,
NCH(CH3)2). dC (125.68 MHz, CDCl3): 161.40, 158.53, 154.40, 137.34, 136.95,
134.49, 131.08, 128.75, 128.21, 127.68, 110.91, 68.02, 42.73, 23.23. ES 1 HRMS:
Calculated M 1 H 5 347.1872. C21H23N4O. Obtained: 347.1873.
Biological assays.Cell culture. T. brucei subsp. brucei, strain Lister 427 VSG 221 were
grown in axenic culture at 37uCand 5%CO2 inHMI-9media supplementedwith 10%
heat-inactivated foetal bovine serum (Gibco).
Trypanotoxicity assays. The sensitivity of trypanosomes to the whole library of purine
derivatives was assessed using resazurin sodium protocol as described previously42.
Exponentially growing parasites were harvested and prepared at initial density of 23
105 trypanosomes per mL. Each well of a 96-well tissue culture plate containing 50 mL
from a serial doubling dilutions of drug was inoculated with 50 mL of trypanosome
culture, with the exception of two rows which received only media. Eleven different
final concentrations of compounds, ranging from 0.5 to 500 mMper assay were tested
in a six-replicate format. Each assay was repeated three times. The same volume of
solvent (DMSO) at each concentration set point was tested in parallel. Parasites were
incubated for 20 h at 37uC and 5% CO2. Then, 20 mL of 0.5 mM resazurin dye
(Sigma, R7017) was added to each well and plates were incubated for a further 4 h.
The reaction was stopped by adding 50 mL of 3%sodium dodecyl sulfate (SDS) in PBS
and then read on a Tecan Infinite F200 reader (Tecan Austria GmbH, Austria) using
an excitation wavelength of 535 nm and an emission wavelength of 590 nm. Half-
inhibitory concentration (IC50) value was calculated using GraphPad Prism5
Software and defined as the concentration of drug required to diminish fluorescence
output by 50%. Data are expresses as the IC50 mean value 6 standard error of the
mean (S.E.M.)
Confocal Microscopy. Morphological phenotype was analyzed by fluorescence and
optical microscopy (DIC, Differential Interference Contrast). After 24 hours of
purines treatment using their IC50 concentration values, parasites were fixed in 4%
paraformaldehyde (PFA). Then, trypanosomes were washed three times and spread
on poly-L-lysine-coated slides and mounted in DAPI-containing Vectashield med-
ium (Vector Laboratories, Burlingame, CA, USA). Image acquisition was performed
with Confocal Scanning Microscope Zeiss LSM 710 and Zen 2012 software.
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